Answers are grounded in this paper and cite their sources.
Retrospective analysis evaluates PD-L1 expression discordance in advanced NSCLC, suggesting variability in immunotherapy selection processes.
e14579 Background: PD-L1 expression guides immunotherapy selection in NSCLC, yet multiple assays are used interchangeably despite known analytic variability. Real-world concordance across PD-L1 assays in community oncology practice is poorly characterized. Methods: We retrospectively analyzed PDL-1 expression data among 40 advanced NSCLC patients diagnosed in 2024 at a community oncology practice. PD-L1 testing was performed on each specimen using 22C3 (Pembrolizumab), 28-8 (Nivolumab), and SP142 assays (Atezolizumab). Positivity patterns (1% or higher) and inter-assay concordance were evaluated. Results: Among 40 Metastatic NSCLC patients, 40 underwent PD-L1 testing. 35 patients had all three assays performed on the same specimen (n = 35) PD-L1 positivity rates differed substantially: Complete concordance across all three assays occurred in only 11 PDL-1 positive patients (31%), while 10 (29%) were PDL-1 negative across all assays. Clinically significant discordance was frequent: 12 patients (34%) were positive by 22C3 and 28-8 but negative by SP142 Additional discordance included isolated positivity by 28-8 (n = 1) or SP142 (n = 1). In total PDL-1 assay discordance was seen in 14/35 patients (40%). Conclusions: Substantial inter-assay variability in PD-L1 expression in the same tissue specimen was observed in this community NSCLC cohort. However, due to concerns regarding costs and tissue exhaustion, additional and ongoing real-world data needs to be explored to determine the clinical utility of multiple versus a single umbrella PDL-1 assay in this setting.
No takes yet. Share an insight, caveat, or question.
Usman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: